Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Conjugated proteins

A protein, conjugation technology, applied in the field of modified proteins

Inactive Publication Date: 2012-12-05
NOVO NORDISK AS
View PDF8 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clinical presentation is not in primary hemostasis—clot formation occurs normally—but in clot instability due to lack of subsequent thrombin formation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Conjugated proteins
  • Conjugated proteins
  • Conjugated proteins

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0204] Production of recombinant B-domain truncated O-glycosylated factor VIII

[0205] Cell Lines and Culture Methods

[0206] Mammalian expression plasmids were constructed using Factor VIII cDNA. The plasmid encodes Factor VIII with a B domain deletion, a Factor VIII heavy chain comprising amino acids 1-740 of full-length human Factor VIII, a Factor VIII light chain comprising amino acids 1649-2332 of full-length human Factor VIII (this molecule may be referred to herein as for "N8", see Thim et al., Haemophilia (2010) 16 , 349). The heavy and light chain sequences are separated by a 21 amino acid linker (SFSQNSRHPSQNPPVLKRHQR- SEQ ID NO 4 ) linkage, the linker comprising the sequence of amino acids 741-750 and 1638-1648 of full-length human Factor VIII. Chinese hamster ovary (CHO) cells were transfected with the plasmid, selected with the dihydrofolate reductase system, and finally produced clonal suspension producer cells cultured in animal component-free medium....

Embodiment 2

[0217] Conjugation of C-16 fatty diacid γ-Glu NHS ester to GSC to obtain sialyltransferase substrate 1

[0218]

[0219] GSC (glycylsialic acid CMP ester) (7.5 mg, 11 μmol) was dissolved in a mixture of TRIS buffer (100 mM, pH 8.4, 50 μl) and acetonitrile 50 μl. A two-phase system is obtained. C-16 fatty diacid γ-Glu NHS ester (7 mg; see WO 2005 / 012347 A2 Example 5 for the preparation of the analogue C-18 compound) was dissolved in THF (50 μl) and TRIS-buffer was added (50 μl), a clear solution was obtained. This solution was added to the solution of GSC. A clear solution was obtained. After about 4 hours of reaction time, the samples were concentrated in vacuo to remove most of the organic solvent and then frozen at -20°C. product( 1 ) identified by HPLC and LC-MS.

[0220] Purified by RP-HPLC using a neutral buffer system and a C4 Jupiter 10x250 cm column. Flow rate 5 ml / min, gradient 2% B buffer / min. collection of products 1 late elution fraction. Fractions w...

Embodiment 3

[0222] Example 3. Preparation of albumin binder NHS ester 2

[0223]

[0224] Rink-amide resin (Novabiochem, 0.4 g, 0.25 mmol) was used for synthesis on a CEM Liberty microwave peptide synthesizer. A standard Fmoc chemistry scheme was employed and the following amino acids used were used in this order (all solutions had 7 equivalents of amino acids in NMP containing 0.3 M HOAt):

[0225] 1. Fmoc-Lys(Mtt)-OH: 1.12 g / 6 ml

[0226] 2. Fmoc-OEG-OH: 1.39 g / 12 ml (2 couplings)

[0227] 3. Fmoc-Glu-OtBu: 0.77 g / 6 ml

[0228] 4. Fmoc-Thx-OH: 0.68 g / 6 ml

[0229] 5. Mono-tert-butyl C-16 diacid (see Example 4 of WO 2005 / 012347 A2): 0.62 g / 6 ml

[0230] All couplings were performed by addition of DIC 7 eq.

[0231] After these couplings, the resin was removed from the Liberty synthesizer and washed, drained, and treated with 5 ml of hexafluoroisopropanol for 10 minutes. The resin was then washed with DCM and drained. Then, the hexafluoroisopropanol treatment and DCM wash were...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to modified therapeutic proteins, such as e.g. coagula- tion factors. In particular, the present invention relates to conjugated Factor VIII molecules such as e.g. FVII, FVIII, or FIX comprising a hydrophobic side group.

Description

field of invention [0001] The present invention relates to modified proteins. In particular, the invention relates to proteins such as coagulation factors conjugated to hydrophobic side groups. Furthermore, the invention relates to the use of such molecules and methods for producing such molecules. Background of the invention [0002] Hemophilia A is an inherited bleeding disorder caused by a deficiency or dysfunction of clotting factor VIII (FVIII). The clinical presentation is not in primary hemostasis—clot formation occurs normally—but in clot instability due to lack of subsequent thrombin formation. The disease is treated by intravenous injection of clotting factor FVIII isolated or recombinantly produced from blood. Hemophilia A patients with inhibitors can be treated with on-demand administration of Factor Vila (FVIIa). Hemophilia B is caused by lack of activity or dysfunction of clotting factor IX (FIX), and patients can be treated with on-demand administration o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/745C07K14/755
CPCA61K47/14C12N9/6437C12Y304/21021C12Y304/21022C12N9/644C07K14/745C07K14/755A61P7/04A61P29/00
Inventor J.布查特C.贝伦斯
Owner NOVO NORDISK AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com